Eli Lilly slips, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.
The Eli Lilly and Novo Nordisk logos. The market share of India's most popular weightloss drugmaker, Eli Lilly, slipped in March, while rival Novo Nordisk held steady even as Indian generic drugmake…
Originally published by CNBC. Read the full article →
More from India
ADB suggests unified social protection framework to cut duplication
Outlining the policy challenges in India, ADB, in its Asia Development Outlook report said multiple central and state schemes serve overlapping beneficiary groups, with limited coordination on eligibility, benefit levels, or delivery
The News Flicker·April 10, 2026
Dhurandhar 2 1st Film To Cross Rs 1,000 Cr
Aditya Dhar's Dhurandhar The Revenge has made cinematic history by becoming the first Indian film to achieve a staggering Rs 1,000 crore (Rs 10 billion) in nett collections, exclusively from its Hindi version within India.
The News Flicker·April 10, 2026
Chinese Refiners Buy Iranian Crude at Premium
Chinese independent refiners are buying Iranian crude at a premium to Brent crude, for the first time in years, Reuters has reported, noting prices were driven higher by anticipated increases in Indian purchases of Iranian oil. At least two so-called teapot r…
The News Flicker·April 10, 2026